Cardiff Oncology to Present Updated Data on RAS-Mutated Colorectal Cancer Treatment
Event summary
- Cardiff Oncology will present updated Phase 2 data (CRDF-004 trial) at the ASCO 2026 Annual Meeting on June 2, 2026.
- The trial evaluates onvansertib in combination with standard of care (FOLFIRI/bevacizumab or FOLFOX/bev) for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC).
- The abstract (number 3510) will be publicly available on ASCO’s website starting May 21, 2026.
- Onvansertib is a PLK1 inhibitor being investigated for multiple cancers, including mPDAC, SCLC, TNBC, and CMML.
The big picture
The presentation of CRDF-004 data represents a key inflection point for Cardiff Oncology, as it seeks to validate onvansertib's efficacy in a significant, underserved patient population. RAS mutations are increasingly recognized as a critical therapeutic target in mCRC, and the success of onvansertib could establish Cardiff Oncology as a player in this evolving oncology space. However, the mCRC market is highly competitive, with numerous other therapies in development, making the ASCO presentation and subsequent data analysis critical for investor sentiment and future strategic decisions.
What we're watching
- Clinical Efficacy
- The interim results presented at ASCO will be crucial in determining whether onvansertib demonstrates sufficient clinical benefit to warrant further development and potential regulatory approval, particularly given the competitive landscape in mCRC.
- Regulatory Pathway
- The strength of the ASCO data will heavily influence Cardiff Oncology’s strategy for engaging with regulatory agencies, potentially impacting the timeline and requirements for a potential Biologics License Application (BLA).
- Competitive Dynamics
- How the data is received relative to other emerging therapies targeting RAS mutations will shape Cardiff Oncology’s positioning and commercial prospects within the crowded mCRC treatment market.
Related topics